


Page 1

L1 STRUCTURE UPLOADED
L2 8 L1 SSS FULL

L3 FILE 'CAPLUS' ENTERED AT 16:54:59 ON 23 APR 2003
4 L2

=> d que stat 13
L1 STR



G1

Structure attributes must be viewed using STN Express query preparation.

L2 8 SEA FILE=REGISTRY SSS FUL L1
L3 4 SEA FILE=CAPLUS ABB=ON PLU=ON L2

=> d l3 total ibib abs hitstr

L3 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:884126 CAPLUS
DOCUMENT NUMBER: 134:147764
TITLE: Micellization of Hydrophobically Modified
Cyclodextrins: 2. Inclusion of Guest Molecules
AUTHOR(S): Auzely-Velty, R.; Pean, C.; Djedaieni-Pilard, F.;
Zemb, Th.; Perly, B.
CORPORATE SOURCE: Service de Physico-Chimie Analytique, Institut de
Recherches SERVIER, Suresnes, 92150, Fr.
SOURCE: Langmuir (2001), 17(2), 504-510
CODEN: LANGD5; ISSN: 0743-7463
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The association of guest mols. in aggregates of a modified cyclodextrin,
6I-(cholest-5-en-3 α -ylamido)succinylamido-6I-deoxy-per(2,6-di-O-
methyl)cyclomaltoheptaose, was investigated for four different sparingly
water-soluble mols. and an anionic surfactant (sodium dodecyl sulfate). The
binding and spatial proximities were demonstrated for these different
guests by NMR (nuclear Overhauser effect pumping). By use of small-angle
X-ray and neutron scattering, the microstructure at the supramol. scale of

23/04/2003<L> 16:56

the modified cyclodextrin micelle, i.e., aggregation number, charge, and volume, in the presence of guest mols. could be defined. From the anal. of the variations in terms of aggregation number and charge induced by the presence of the guest mol., the cavity of the cyclodextrin was shown to remain available for solubilization and transport. The stability and specificity of the mixed micelle involving target mols. demonstrated here make these hydrophobically modified cyclodextrins good candidates as mol. carriers.

IT 324020-36-2P 324020-37-3P 324020-39-5P

324020-40-8P 324020-41-9P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(micellization and inclusion of hydrophobically modified cyclodextrins)

RN 324020-36-2 CAPLUS

CN β -Cyclodextrin, 6A-[[4-[(3 α)-cholest-5-en-3-ylamino]-1,4-dioxobutyl]amino]-6A-deoxy-2A,2B,2C,2D,2E,2F,2G,6B,6C,6D,6E,6F,6G-trideca-O-methyl-, compd. with methyl α -D-mannopyranoside (1:1) (9CI) (CA INDEX NAME)


CM 1


CRN 269745-79-1

CMF C86 H146 N2 O36

Absolute stereochemistry.

PAGE 1-A






CM 2

CRN 617-04-9

CMF C7 H14 O6

Absolute stereochemistry.



RN 324020-37-3 CAPLUS




CN β-Cyclodextrin, 6A-[[4-[(3α)-cholest-5-en-3-ylamino]-1,4-dioxobutyl]amino]-6A-deoxy-2A,2B,2C,2D,2E,2F,2G,6B,6C,6D,6E,6F,6G-trideca-O-methyl-, compd. with (3Z)-3-dibenzo[b,e]thiepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine hydrochloride (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 269745-79-1

CMF C86 H146 N2 O36

Absolute stereochemistry.




CM 2

CRN 25627-39-8

CMF C19 H21 N S . Cl H

Double bond geometry as shown.



● HCl

RN 324020-39-5 CAPLUS




CN β -Cyclodextrin, 6A-[[4-[(3 α)-cholest-5-en-3-ylamino]-1,4-dioxobutyl]amino]-6A-deoxy-2A,2B,2C,2D,2E,2F,2G,6B,6C,6D,6E,6F,6G-trideca-O-methyl-, compd. with 2,2-dichloro-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 269745-79-1

CMF C86 H146 N2 O36


Absolute stereochemistry.



CM 2

CRN 56-75-7
CMF C11 H12 C12 N2 O5

Absolute stereochemistry. Rotation (-).




RN 324020-40-8 CAPLUS
CN β -Cyclodextrin, 6A-[4-[(3 α)-cholest-5-en-3-ylamino]-1,4-dioxobutyl]amino]-6A-deoxy-2A,2B,2C,2D,2E,2F,2G,6B,6C,6D,6E,6F,6G-trideca-O-methyl-, compd. with sodium dodecyl sulfate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 269745-79-1
CMF C86 H146 N2 O36

Absolute stereochemistry.

PAGE 1-A





CM 2

CRN 151-21-3

CMF C12 H26 O4 S . Na

HO₃SO- (CH₂)₁₁-Me

● Na

RN 324020-41-9 CAPLUS




CN β-Cyclodextrin, 6A-[[4-[(3α)-cholest-5-en-3-ylamino]-1,4-dioxobutyl]amino]-6A-deoxy-2A,2B,2C,2D,2E,2F,2G,6B,6C,6D,6E,6F,6G-trideca-O-methyl-, compd. with sodium 4-(1,1-dimethylethyl)benzoate (1:1) (9CI)
(CA INDEX NAME)

CM 1


CRN 269745-79-1

CMF C86 H146 N2 O36

Absolute stereochemistry.



CRN 17264-53-8
CMF C11 H14 O2 . Na



● Na

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:790552 CAPLUS

DOCUMENT NUMBER: 133:351719

TITLE: Amphiphilic cyclodextrins, their preparation and use for solubilizing and transporting hydrophobic molecules in aqueous media

INVENTOR(S): Auzely-Velty, Rachel; Perly, Bruno; Djedaini-Pilard, Florence

PATENT ASSIGNEE(S): Commissariat a l'Energie Atomique, Fr.

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066635	A1	20001109	WO 2000-FR1102	20000426
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2792942	A1	20001103	FR 1999-5460	19990429
FR 2792942	B1	20010608		
EP 1177217	A1	20020206	EP 2000-922751	20000426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002543249	T2	20021217	JP 2000-615663	20000426
PRIORITY APPLN. INFO.:			FR 1999-5460	A 19990429
			WO 2000-FR1102	W 20000426
OTHER SOURCE(S):		MARPAT 133:351719		
GI				



- AB Cyclodextrin derivs. of formula I [R1 = steroid residue; R2 = (un)substituted alkyl or aryl; R3 = H, R2; R4 = OR2, or 1 R4 = NHCO(CH₂)_mCONHR1] are useful for transporting hydrophobic mols. for pharmaceutical or cosmetic uses, by forming organized systems in an aqueous medium, independently or associated with phospholipids. Thus, 6-azido-6-deoxy-β-cyclodextrin was methylated on the OH groups in the 2 and 6 positions to a tridecamethyl ether, which was converted to the amine, treated with succinic anhydride, and the product amidated with cholest-5-en-3α-ylamine to give I (R1 = cholest-5-en-3α-yl, R2 = Me, R3 = H, R4 = OMe, m = 2, n = 6) (II). An aqueous solution of II at a concentration above its critical micelle concentration formed spherical nanoparticles of diameter 60 Å, which could form inclusion compds. with fatty acids and other hydrophobic mols.
- IT **269745-79-1P**
 RL: BUU (Biological use, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (amphiphilic cyclodextrins for solubilizing and transporting hydrophobic mols. in aqueous media)
- RN 269745-79-1 CAPLUS
- CN β-Cyclodextrin, 6A-[[4-[(3α)-cholest-5-en-3-ylamino]-1,4-dioxobutyl]amino]-6A-deoxy-2A,2B,2C,2D,2E,2F,2G,6B,6C,6D,6E,6F,6G-trideca-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:164867 CAPLUS

DOCUMENT NUMBER: 132:347811

TITLE: Micellization of Hydrophobically Modified
Cyclodextrins. 1. Micellar Structure

AUTHOR(S): Auzely-Velty, R.; Djedaïeni-Pilard, F.; Desert, S.;
Perly, B.; Zemb, Th.

CORPORATE SOURCE: Service de Chimie Moléculaire DRECAM CEA Saclay, Gif
sur Yvette, F-91191, Fr.

SOURCE: Langmuir (2000), 16(8), 3727-3734

CODEN: LANGD5; ISSN: 0743-7463

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The grafting of a cholesterol derivative onto a methylated cyclodextrin
through a spacer arm produces an amphiphilic compound exhibiting high
solubility

in water. This new mol. was fully characterized in terms of chem. and
optical purities by high resolution NMR and mass spectrometry. An anal. of
its behavior in aqueous solution using surface tension measurements and light,
small-angle X-ray, and neutron scattering techniques proved that it
self-assembles into monodisperse spherical micelles with an average
aggregation number of 24. The micelles can be described as two-shell
objects, the cyclodextrin moieties being exposed to the aqueous medium, making
them prone to include guest mols. in the cavities. These objects can
therefore be of high interest for the targeting of biol. important mols.
and especially for the delivery of drugs.

IT 250256-27-0



RL: PRP (Properties)

(preparation and micellization of hydrophobically modified cyclodextrins)

RN 250256-27-0 CAPLUS

CN β -Cyclodextrin, 6A-[[4-[(3 α)-cholest-5-en-3-ylamino]-1,4-
dioxobutyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 269745-79-1P


RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)

(preparation and micellization of hydrophobically modified cyclodextrins)
 RN 269745-79-1 CAPLUS
 CN β -Cyclodextrin, 6A-[[4-[(3 α)-cholest-5-en-3-ylamino]-1,4-dioxobutyl]amino]-6A-deoxy-2A,2B,2C,2D,2E,2F,2G,6B,6C,6D,6E,6F,6G-trideca-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:568419 CAPLUS
 DOCUMENT NUMBER: 131:351563
 TITLE: Cholesteryl-cyclodextrins: synthesis and insertion into phospholipid membranes
 AUTHOR(S): Auzely-Velty, R.; Perly, B.; Tache, O.; Zemb, T.; Jehan, P.; Guenot, P.; Dalbierz, J.-P.; Djedaini-Pilard, F.
 CORPORATE SOURCE: CEA Saclay, Service de Chimie Moleculaire DRECAM, Gif sur Yvette, F-91191, Fr.
 SOURCE: Carbohydrate Research (1999), 318(1-4), 82-90
 CODEN: CRBRAT; ISSN: 0008-6215
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB 6I-(Cholest-5-en-3 β -yloxy carbonyl) amino-6I-deoxycyclomaltoheptaose and 6I-(cholest-5-en-3 α -ylamido)succinylamido-6I-deoxycyclomaltoheptaose were synthesized and fully characterized by NMR spectroscopy expts. and mass spectrometry anal. Incorporation of these monosubstituted amphiphilic cyclodextrins into phospholipid bilayers was investigated using small-angle X-ray scattering, differential scanning calorimetry and ³¹P NMR. Different modes of incorporation depending on the spacer length between the cyclodextrin and cholesterol moieties were observed

IT 250256-28-1P

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)

(cholesteryl cyclodextrins synthesis and insertion into phospholipid membranes)

RN 250256-28-1 CAPLUS

CN β -Cyclodextrin, 6A-[[4-[(3 α)-cholest-5-en-3-ylamino]-1,4-dioxobutyl]amino]-6A-deoxy-, compd. with (7R)-4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-3,5,9-trioxa-4-phosphatricosan-1-aminium inner salt 4-oxide (1:1) (9CI) (CA INDEX NAME)


CM 1


CRN 250256-27-0

CMF C73 H120 N2 O36

Absolute stereochemistry.

PAGE 1-A






CM 2

CRN 18194-24-6

CMF C36 H72 N O8 P

Absolute stereochemistry.





IT 250256-27-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (cholesteryl cyclodextrins synthesis and insertion into phospholipid membranes)

RN 250256-27-0 CAPLUS

CN β-Cyclodextrin, 6A-[[4-[(3α)-cholest-5-en-3-ylamino]-1,4-dioxobutyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

31

THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d que stat l14
L1 STR



G1

Structure attributes must be viewed using STN Express query preparation.

L2 485 SEA FILE=REGISTRY SSS FUL L1
L3 97 SEA FILE=CAPLUS ABB=ON PLU=ON L2
L13 61 SEA FILE=CAPLUS ABB=ON PLU=ON L3 AND CYCLODEXTRIN
L14 34 SEA FILE=CAPLUS ABB=ON PLU=ON L13 NOT PY>1999

=> d l14 total ibib abs hitstr

L14 ANSWER 1 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:87172 CAPLUS

DOCUMENT NUMBER: 132:279412

TITLE: Investigation of cyclomaltooligosaccharide-bound
6-(4-methoxyphenyl)imidazo[1,2-a]pyrazin-3(7 H)-one
for enhanced chemiluminescence

AUTHOR(S): Teranishi, Katsunori; Tanabe, Saori; Hisamatsu,
Makoto; Yamada, Tetsuya

CORPORATE SOURCE: Faculty of Bioresources, Mie University, Tsu,
514-8507, Japan

SOURCE: Luminescence (1999), 14(6), 303-314

CODEN: LUMIFC; ISSN: 1522-7235

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The chemiluminescence compound 2-methyl-6-(4-methoxyphenyl)imidazo[1,2-a]pyrazin-3(7H)-one (MCLA) was attached to cyclomaltooligosaccharides (**cyclodextrins**) through a single spacer by the formation of an amide bond. The properties of oxygen-induced chemiluminescence of the synthesized **cyclodextrin**-bound MCLA were investigated in an aqueous phosphate buffer, pH 8.0. The light-emitting efficiency was remarkably dependent on the kind of bound **cyclodextrin**, spacer length between the MCLA and **cyclodextrin**, and the binding site in **cyclodextrin**. The light-emitting efficiencies of cyclomaltooctaose (γ -**cyclodextrin**)-bound compds. were higher than those of cyclomaltohexaose- or cyclomaltoheptaose-bound compds. Especially, compds. in which MCLA attached to the secondary side of γ -**cyclodextrin** through a short chain showed an up to 44-fold enhancement over that of a non-**cyclodextrin** compound. In the current case, the efficiency of single excited-state formation was 23

times greater than that of the non-**cyclodextrin** compound and significantly responsible for greater light-emitting efficiency. The chemiluminescence spectra indicated the wide entrance of the secondary side of γ -**cyclodextrin**, and the short spacer allowed suitable intramol. affinity between the singlet excited-state chromophore moiety and the **cyclodextrin**.

IT 263905-29-9P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)


(investigation of cyclomaltooligosaccharide-bound 6-(methoxyphenyl)imidazo[1,2-a]pyrazinone for enhanced chemiluminescence)

RN 263905-29-9 CAPLUS


CN γ -Cyclodextrin, 6A-deoxy-6A-[[4-[[5-(4-methoxyphenyl)pyrazinyl]amino]-1,4-dioxobutyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B




PAGE 1-C




PAGE 2-A

MeO

PAGE 2-B





REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:56515 CAPLUS

DOCUMENT NUMBER: 132:339156

TITLE: Pharmacological investigations of new peptidocyclodextrins

AUTHOR(S): Pean, C.; Wijkhuisen, A.; Djedaini-Pilard, F.; Creminon, C.; Grassi, J.; Perly, B.

CORPORATE SOURCE: DRECAM/SCM, CEA-Saclay, Gif sur Yvette, F-91191, Fr.
SOURCE: Proceedings of the International Symposium on Cyclodextrins, 9th, Santiago de Comostela, Spain, May 31-June 3, 1998 (1999), Meeting Date 1998, 387-390.
Editor(s): Labandeira, J. J. Torres; Vila-Jato, J. L.
Kluwer Academic Publishers: Dordrecht, Neth.
CODEN: 68NHAE

DOCUMENT TYPE: Conference

LANGUAGE: English

AB In a previous work, the authors synthesized and characterized eight new different peptidocyclodextrins. They are composed with a β - or γ -CD part, and a peptidic part constituted of the neuropeptide Substance P (noted SP, H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂) or one of its derivs., the SP 4-11. Products obtained were β - or γ -CD(Lys3)-SP, β - or γ -CD(Arg1)-SP, di- β - or di- γ -CD(Arg1, Lys3)-SP (noted CD-SP) and β - or γ -CD-SP 4-11. In this communication, the authors report in vitro pharmacol. investigations of these CD-SP. The authors demonstrate the recognition properties of the diverse conjugates by SP receptor mimics (anti SP polyclonal antibodies), by recombinant human NK1 receptor (using binding expts. on CHO transfected cells) and the production of the second messengers inositol phosphates induced by fixation of the CD-SP on the NK1 receptor. These studies form the basis for the next steps: (1) in vivo studies of the CD-SP conjugates, and (2) the evaluation of their potential use as mol. carriers for drug targeting.

IT 251374-54-6 251374-55-7 251374-56-8

251374-57-9 251374-58-0 251374-59-1

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)


(pharmacol. investigations of new substance P **cyclodextrins** and potential use in drug targeting)

RN 251374-54-6 CAPLUS

CN L-Methioninamide, 1-[4-[(6A-deoxy- β -cyclodextrin-6A-yl)amino]-1,4-dioxobutyl]-L-prolyl-L-glutaminy-L-glutaminy-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 2-A



PAGE 3-A









RN 251374-55-7 CAPLUS

CN L-Methioninamide, N2-[4-[(6A-deoxy- β -cyclodextrin-6A-yl)amino]-1,4-dioxobutyl]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.








PAGE 3-B



RN 251374-56-8 CAPLUS



CN L-Methioninamide, L-arginyl-L-prolyl-N6-[4-[(6A-deoxy-β-cyclodextrin-6A-yl)amino]-1,4-dioxobutyl]-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A











PAGE 2-B

RN 251374-58-0 CAPLUS
 CN L-Methioninamide, N2-[4-[(6A-deoxy-γ-cyclodextrin-6A-yl) amino]-1,4-dioxobutyl]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminy-L-glutaminy-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 1-C




PAGE 2-C






RN 251374-59-1 CAPLUS
 CN L-Methioninamide, L-arginyl-L-prolyl-N6-[4-[(6A-deoxy-γ-cyclodextrin-6A-yl) amino]-1,4-dioxobutyl]-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B





REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:56453 CAPLUS

DOCUMENT NUMBER: 132:233519

TITLE: Thiamine-appended **cyclodextrin** dimer as a ligase model

AUTHOR(S): Ikeda, H.; Horimoto, Y.; Nakata, M.; Ueno, A.

CORPORATE SOURCE: Department of Bioengineering, Faculty of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, 226-8501, Japan

SOURCE: Proceedings of the International Symposium on Cyclodextrins, 9th, Santiago de Comostela, Spain, May 31-June 3, 1998 (1999), Meeting Date 1998, 129-132. Editor(s): Labandeira, J. J. Torres; Vila-Jato, J. L. Kluwer Academic Publishers: Dordrecht, Neth. CODEN: 68NHAE


DOCUMENT TYPE: Conference



LANGUAGE:


English

- AB In this symposium we present the synthesis and characterization of a thiazolium-appended β - **cyclodextrin** dimer for the benzoin condensation reaction. This enzyme model effectively catalyzes the benzoin condensation of benzaldehyde.
- IT **262299-51-4P**
 RL: BSU (Biological study, unclassified); CAT (Catalyst use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (thiamine-appended **cyclodextrin** dimer as a ligase model)
- RN 262299-51-4 CAPLUS
- CN β -Cyclodextrin, 6A,6'A-[[(2S)-2-[[(4-methylthiazolium-3-yl)acetyl]amino]-1,4-dioxo-1,4-butanediyl]diimino]bis[6-deoxy- (9CI) (CA INDEX NAME)

PAGE 1-A







REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:56450 CAPLUS

DOCUMENT NUMBER: 132:237271

TITLE: The synthesis of oligosaccharide-branched **cyclodextrins**

AUTHOR(S): Inazu, Toshiyuki; Yamanoi, Takashi; Haneda, Katsuji; Mizuno, Mamoru; Matsuda, Keisuke; Yamazaki, Tomohiro; Takeuchi, Masahito; Tsurui, Hisayo; Hattori, Kenjiro

CORPORATE SOURCE: The Noguchi Institute, Tokyo, 173-0003, Japan

SOURCE: Proceedings of the International Symposium on Cyclodextrins, 9th, Santiago de Comostela, Spain, May 31-June 3, 1998 (1999), Meeting Date 1998, 117-120.

DOCUMENT TYPE: Conference

LANGUAGE: English

AB Large-scale preparation of oligosaccharide amino acid-branched **cyclodextrins** is reported.



IT 197509-30-1P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(The synthesis of oligosaccharide-branched **cyclodextrins**)

RN 197509-30-1 CAPLUS


CN β -Cyclodextrin, 6A-deoxy-6A-[[(2S)-4-[[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]amino]-2-[[(9H-fluoren-9-ylmethoxy) carbonyl]amino]-1,4-dioxobutyl]amino]- (9CI) (CA INDEX NAME)





PAGE 2-A

PAGE 2-B



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:744871 CAPLUS

DOCUMENT NUMBER: 132:116833

TITLE: Fluorescent molecular recognition systems of terphenyl modified β - and γ - **cyclodextrins**

AUTHOR(S): Ito, Shigeki; Narita, Miyuki; Hamada, Fumio

CORPORATE SOURCE: Department of Materials-process Engineering, Akita University, Akita, 010-8502, Japan


SOURCE: International Journal of the Society of Materials Engineering for Resources (1999), 7(1), 156-165

PUBLISHER: CODEN: IMEREB

DOCUMENT TYPE: Society of Materials Engineering for Resources of Japan

LANGUAGE: Journal

GI English



I

AB Terphenyl-modified β - and γ - **cyclodextrin** analogs (I, a n=6; b n=7) were prepared to study their fluorescent mol. sensor ability for organic guests, such as terpenoids or bile acids. These hosts show a pure monomer fluorescence with increasing or decreasing by accommodation of a guest. The extent of fluorescence variation with a guest was used to display the sensing ability of those host mols. Host Ia detects smaller guests such as terpenoids with much higher sensitivity in a 10 volume-% DMSO aqueous solution than those of in a 20 volume-% DMSO aqueous solution

However, larger

guests such as bile acids were detected with less sensitivity in a 20 volume-% DMSO aqueous solution by Ia. The sensing ability of Ib for a guest examined

was hardly effected by the solvent. The mol. sensing system combined with Ia and Ib could be useful method, because their binding behaviors for guests are different, in which the parameter values indicating the sensing ability obtained from Ia were almost pos., whereas the parameter ones for Ib were neg.



IT **255061-44-0P 255061-45-1P**

RL: ARU (Analytical role, unclassified); PRP (Properties); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation)
(fluorescent mol. recognition systems of terphenyl modified β - and γ - **cyclodextrins**)

RN 255061-44-0 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[1,4-dioxo-4-([1,1':4',1''-terphenyl]-4-ylamino)butyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 255061-45-1 CAPLUS


CN γ -Cyclodextrin, 6A-deoxy-6A-[[1,4-dioxo-4-([1,1':4',1''-terphenyl]-4-ylamino)butyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B




PAGE 1-C




PAGE 2-A

Ph

PAGE 2-B



PAGE 2-C



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:669963 CAPLUS

DOCUMENT NUMBER: 132:122826

TITLE: Preparation and guest binding of novel β -**cyclodextrin** dimers linked with various sulfur-containing linker moieties

AUTHOR(S): Yamamura, Hatsuo; Yamada, Shinichi; Kohno, Keiko; Okuda, Nozomi; Araki, Shuki; Kobayashi, Kyoko;

CORPORATE SOURCE: Katakai, Ryoichi; Kano, Kazuaki; Kawai, Masao Showa-ku, Gokiso-cho, Department of Applied Chemistry, Nagoya Institute of Technology, Nagoya, 466-8555, Japan

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1999), (20), 2943-2948

CODEN: JCPRB4; ISSN: 0300-922X

PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 132:122826

AB **Cyclodextrin** dimers with sulfur-containing linkers, namely a thiodipropanamide, a dithiodipropanamide, a thiodiethanamide, or a dithiodiethanamide linker, were synthesized by a reaction of 6-amino-6-deoxycycloheptaose with the corresponding dicarboxylic acids. For their preparation, dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate were examined as coupling reagents. ¹H NMR studies of the dimers suggested an intramol. inclusion of the linker moiety to the **cyclodextrin** cavity, which affected the complexation of aryl sulfonate guest mols.

IT 256430-98-5P 256430-99-6P 256431-00-2P
 256431-02-4P 256444-50-5P 256444-51-6P
 256444-52-7P 256444-53-8P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and guest binding of novel β -**cyclodextrin** dimers
 linked with various sulfur-containing linker moieties)

RN 256430-98-5 CAPLUS


CN β -Cyclodextrin, 6A,6'A-[(1,6-dioxo-1,6-hexanediyl)diimino]bis[6A-deoxy-, compd. with sodium 4-[[4-(dimethylamino)phenyl]azo]benzenesulfonate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 256430-97-4

CMF C90 H148 N2 O70


PAGE 1-A



PAGE 2-A




PAGE 3-A



CM 2

CRN 547-58-0

CMF C14 H15 N3 O3 S . Na




● Na



RN 256430-99-6 CAPLUS
 CN β -Cyclodextrin, 6A,6'A-[(1,6-dioxo-1,6-hexanediyl)diimino]bis[6A-deoxy-, compd. with 4-[[4-(phenylamino)phenyl]azo]benzenesulfonic acid monosodium salt (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 256430-97-4
 CMF C90 H148 N2 O70

PAGE 1-A






CM 2

CRN 554-73-4

CMF C18 H15 N3 O3 S . Na




● Na



RN 256431-00-2 CAPLUS
 CN β-Cyclodextrin, 6A,6'A-[(1,6-dioxo-1,6-hexanediyl)diimino]bis[6A-deoxy-, compd. with 6-[(4-methylphenyl)amino]-2-naphthalenesulfonic acid monosodium salt (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 256430-97-4
 CMF C90 H148 N2 O70

PAGE 1-A






CM 2

CRN 53313-85-2

CMF C17 H15 N O3 S . Na




● Na



RN 256431-02-4 CAPLUS
 CN β-Cyclodextrin, 6A,6'A-[(1,6-dioxo-1,6-hexanediyl)diimino]bis[6A-deoxy-, compd. with 6-[[4-(1,1-dimethylethyl)phenyl]amino]-2-naphthalenesulfonic acid monosodium salt (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 256430-97-4
 CMF C90 H148 N2 O70

PAGE 1-A






CM 2

CRN 144796-65-6

CMF C20 H21 N O3 S . Na




● Na



RN 256444-50-5 CAPLUS
 CN β -Cyclodextrin, 6A,6'A-[(1,5-dioxo-1,5-pentanediy)diimino]bis[6A-deoxy-, compd. with sodium 4-[[4-(dimethylamino)phenyl]azo]benzenesulfonate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 130912-24-2
 CMF C89 H146 N2 O70

PAGE 1-A






CM 2

CRN 547-58-0

CMF C14 H15 N3 O3 S . Na




● Na



RN 256444-51-6 CAPLUS
 CN β -Cyclodextrin, 6A,6'A-[(1,5-dioxo-1,5-pentanediy)diimino]bis[6A-deoxy-, compd. with 4-[[4-(phenylamino)phenyl]azo]benzenesulfonic acid monosodium salt (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 130912-24-2
 CMF C89 H146 N2 O70

PAGE 1-A






CM 2

CRN 554-73-4

CMF C18 H15 N3 O3 S . Na




● Na

RN 256444-52-7 CAPLUS
 CN β -Cyclodextrin, 6A, 6'A-[(1,5-dioxo-1,5-pentanediy)diimino]bis[6A-deoxy-, compd. with 6-[(4-methylphenyl)amino]-2-naphthalenesulfonic acid monosodium salt (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 130912-24-2
 CMF C89 H146 N2 O70


PAGE 1-A



PAGE 2-A




PAGE 3-A



CM 2

CRN 53313-85-2

CMF C17 H15 N O3 S . Na




● Na

RN 256444-53-8 CAPLUS
 CN β -Cyclodextrin, 6A,6'A-[(1,5-dioxo-1,5-pentanediy1)diimino]bis[6A-deoxy-, compd. with 6-[[4-(1,1-dimethylethyl)phenyl]amino]-2-naphthalenesulfonic acid monosodium salt (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 144796-65-6

CMF C20 H21 N O3 S . Na






● Na

CM 2

CRN 130912-24-2

CMF C89 H146 N2 O70







REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:596919 CAPLUS
 DOCUMENT NUMBER: 131:243592
 TITLE: Preparation of sugar chain-linked asparagine active ester derivative and the synthetic intermediate
 INVENTOR(S): Inazu, Toshiyuki; Mizuno, Masamori
 PATENT ASSIGNEE(S): Noguchi Research Institute, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11255807	A2	19990921	JP 1998-82882	19980313
PRIORITY APPLN. INFO.:			JP 1998-82882	19980313
OTHER SOURCE(S):		MARPAT 131:243592		

GI





- AB Disclosed are the title compds. (I; R = Fmoc; R1, R2, R3 = H, monosaccharide, sugar chain; X = Q; wherein Y = CH, N) are prepared by reaction of benzotriazole derivative [II; Z = C(:N+Me2)NMe2, tris(pyrrolidino)phosphonium; Y = same as above] in a aprotic polar solvent with an intermediate (I; R = Fmoc, X = OH; R1, R2, R3, Y = same as above) which is prepared by 9-fluorenylmethoxycarbonylation of sugar chain-linked asparagine obtained by protease treatment of glycoprotein. These compds. are useful for drugs or agrochems. (no data). Thus, 62.4 mg of egg white albumin-derived sugar chain-linked asparagine H-Asn(GlcNAc2Man6)-OH [I; R = H, R1 = Man(α 1 \rightarrow 6) [Man(α 1.fwdarw.3)]Man(α 1 \rightarrow 6), R2 = H, R3 = Man(α 1 \rightarrow 2)-Man(α 1 \rightarrow 3), X = OH] was dissolved in 6.2 mL 1% aqueous NaHCO₃, treated dropwise with a solution of 16 mg N-(9-fluorenyloxycarbonyloxy)succinimide (Fmoc-OSu) in 10 mL 1,4-dioxane, and stirred overnight to give 63 mg I [R = Fmoc, R1 = Man(α 1 \rightarrow 6) [Man(α 1 \rightarrow 3)]Man(.alpha.1 \rightarrow 6), R2 = H, R3 = Man(α 1 \rightarrow 2)-Man(α 1 \rightarrow 3), X = OH]. To a solution of the latter compound (5.0 mg) in 2 mL N-methyl-2-pyrrolidone were added 2.9 μ L 1 M diisopropylethylamine/N-methyl-2-pyrrolidone solution and 1.5 mg benzotriazol-1-yloxy-tris(pyrrolidino)phosphonium hexafluorophosphate, and 3.3 mg 6-monoamino- β - **cyclodextrin** for capturing the active ester formed, and resulting mixture was stirred overnight to give 74% **cyclodextrin**-linked sugar chain [I; R = Fmoc, R1 = Man(α 1 \rightarrow 6) [Man(α 1 \rightarrow 3)]Man(α 1 \rightarrow 6), R2 = H, R3 = Man(α 1 \rightarrow 2)-Man(α 1 \rightarrow 3), X = 6-monoamino- β - **cyclodextrin** residue].
- IT **197509-30-1P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of sugar chain-linked asparagine active ester derivative and synthetic intermediate)
- RN 197509-30-1 CAPLUS
- CN β -Cyclodextrin, 6A-deoxy-6A-[[(2S)-4-[[O- α -D-mannopyranosyl-(1 \rightarrow 3)]-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)]-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)]-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)]-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]amino]-2-[[(9H-fluoren-9-ylmethoxy) carbonyl]amino]-1,4-dioxobutyl]amino]- (9CI)
 (CA INDEX NAME)

PAGE 1-A



PAGE 1-B





L14 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:568419 CAPLUS
 DOCUMENT NUMBER: 131:351563
 TITLE: Cholesteryl-**cyclodextrins**: synthesis and
 insertion into phospholipid membranes
 AUTHOR(S): Auzely-Velty, R.; Perly, B.; Tache, O.; Zemb, T.;
 Jehan, P.; Guenot, P.; Dalbiez, J.-P.;
 Djedaini-Pilard, F.
 CORPORATE SOURCE: CEA Saclay, Service de Chimie Moleculaire DRECAM, Gif
 sur Yvette, F-91191, Fr.
 SOURCE: Carbohydrate Research (1999), 318(1-4), 82-90
 CODEN: CRBRAT; ISSN: 0008-6215
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB 6I-(Cholest-5-en-3 β -yloxycarbonyl)amino-6I-deoxycyclomaltoheptaose
 and 6I-(cholest-5-en-3 α -ylamido)succinylamido-6I-
 deoxycyclomaltoheptaose were synthesized and fully characterized by NMR
 spectroscopy expts. and mass spectrometry anal. Incorporation of these
 monosubstituted amphiphilic **cyclodextrins** into phospholipid
 bilayers was investigated using small-angle X-ray scattering, differential
 scanning calorimetry and ^{31}P NMR. Different modes of incorporation
 depending on the spacer length between the **cyclodextrin** and

cholesterol moieties were observed

IT **250256-28-1P**
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
 (cholesteryl cyclodextrins synthesis and insertion into phospholipid membranes)

RN 250256-28-1 CAPLUS

CN β -Cyclodextrin, 6A-[[4-[(3 α)-cholest-5-en-3-ylamino]-1,4-dioxobutyl]amino]-6A-deoxy-, compd. with (7R)-4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxotetradecyl)oxy]-3,5,9-trioxa-4-phosphatricosan-1-aminium inner salt 4-oxide (1:1) (9CI) (CA INDEX NAME)


CM 1


CRN 250256-27-0

CMF C73 H120 N2 O36

Absolute stereochemistry.

PAGE 1-A






CM 2

CRN 18194-24-6

CMF C36 H72 N O8 P

Absolute stereochemistry.



IT 250256-27-0P



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(cholesteryl cyclodextrins synthesis and insertion into phospholipid membranes)

RN 250256-27-0 CAPLUS

CN β -Cyclodextrin, 6A-[[4-[(3 α)-cholest-5-en-3-ylamino]-1,4-dioxobutyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

31

THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:453456 CAPLUS

DOCUMENT NUMBER: 132:9255

TITLE: In vitro and in vivo studies on the binding capacity of substance P-derived bifunctional ligands dedicated to drug targeting

AUTHOR(S): Wijkhuisen, A.; Pean, C.; Djedaini-Pilard, F.; Fischer, J.; Conrath, M.; Shigemoto, R.; Grassi, J.; Perly, B.; Couraud, J. Y.; Creminon, C.

CORPORATE SOURCE: CEA, DRM/SPI, Saclay, Gif sur Yvette, 91191, Fr.
SOURCE: NATO Science Series, Series A: Life Sciences (1999), 307(Peptidergic G Protein-Coupled Receptors), 157-160
CODEN: NASAF2; ISSN: 1387-6686

PUBLISHER: IOS Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To validate the general concept of drug-targeting (i.e directing a drug towards a specific. biol. relevant site), the authors prepared new compds. by covalently grafting β or γ **cyclodextrin** (β -CD and γ -CD, oligosaccharide mols. capable of including a drug into their cavities) to the N-terminal part of the neuropeptide substance P (SP) acting as a mol. antenna. Biochem. expts., performed on CHO cells expressing the human NK1 receptor for SP, showed that CD-SP compds. were able to bind recombinant receptors with an affinity only slightly decreased compared to that of free SP. Moreover, peptido-**cyclodextrins** exerted agonist action on the recombinant receptors, as revealed by their ability to trigger a production of intracellular messengers in intact CHO cells. Finally, in vivo intracerebral injections of γ -CD-SP in the striatum of rats were shown to induce a massive internalization of the NK1 receptors, clearly revealed by confocal microscopy. Taken together, these results indicate that grafted SP specifically and efficiently targets γ -CD toward NK1 receptor-bearing cells both in vitro and in vivo.

IT 251374-54-6 251374-55-7 251374-56-8

251374-57-9 251374-58-0 251374-59-1


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(substance P-cyclodextran grafts for drug targeting toward NK1 receptor-bearing cells)

RN 251374-54-6 CAPLUS

CN L-Methioninamide, 1-[4-[(6A-deoxy- β -cyclodextrin-6A-yl)amino]-1,4-dioxobutyl]-L-prolyl-L-glutaminy-L-glutaminy-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 2-A



PAGE 3-A







RN 251374-55-7 CAPLUS

CN L-Methioninamide, N2-[4-[(6A-deoxy- β -cyclodextrin-6A-yl)amino]-1,4-dioxobutyl]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminy-L-glutaminy-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




PAGE 2-A



PAGE 2-B






PAGE 3-B


RN 251374-56-8 CAPLUS

CN L-Methioninamide, L-arginyl-L-prolyl-N6-[4-[(6A-deoxy-β-cyclodextrin-6A-yl)amino]-1,4-dioxobutyl]-L-lysyl-L-prolyl-L-glutamyl-L-glutamyl-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-A






RN 251374-57-9 CAPLUS
 CN L-Methioninamide, 1-[4-[(6A-deoxy-γ-cyclodextrin-6A-yl) amino]-1,4-dioxobutyl]-L-prolyl-L-glutaminy-L-glutaminy-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)









PAGE 2-B

RN 251374-58-0 CAPLUS
 CN L-Methioninamide, N2-[4-[(6A-deoxy-γ-cyclodextrin-6A-yl)amino]-1,4-dioxobutyl]-L-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminy-L-glutaminy-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



PAGE 1-C




PAGE 2-C





RN 251374-59-1 CAPLUS
 CN L-Methioninamide, L-arginyl-L-prolyl-N6-[4-[(6A-deoxy-γ-cyclodextrin-6A-yl)amino]-1,4-dioxobutyl]-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-L-phenylalanyl-L-phenylalanylglycyl-L-leucyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B





NH₂



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:396543 CAPLUS

DOCUMENT NUMBER: 131:214547

TITLE: **Cyclodextrin** as carrier of bioactive peptides

AUTHOR(S): Schaschke, Norbert; Fiori, Stella; Fourmy, Daniel; Moroder, Luis

CORPORATE SOURCE: Max-Planck-Institut fur Biochemie, Martinsried, 82152, Germany

SOURCE: Peptides: Frontiers of Peptide Science, Proceedings of the American Peptide Symposium, 15th, Nashville, June 14-19, 1997 (1999), Meeting Date 1997, 315-316. Editor(s): Tam, James P.; Kaumaya, Pravin T. P. Kluwer: Dordrecht, Neth. CODEN: 67UCAR

DOCUMENT TYPE: Conference

LANGUAGE: English

AB A symposium report. Tetra- and heptagastrin peptide/ β -**cyclodextrin** conjugates were prepared and their binding affinities to the CCK- β /gastrin receptor were determined

IT **211360-86-0P 211360-87-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(preparation and **cyclodextrin**-supported bioactive peptides)

RN 211360-86-0 CAPLUS

CN L-Phenylalaninamide, N-[4-[(6A-deoxy- β -cyclodextrin-6A-yl)amino]-1,4-dioxobutyl]-L-tryptophyl-L-norleucyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




PAGE 2-A





PAGE 2-A

PAGE 3-A



PAGE 3-B

—CO₂H

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:738359 CAPLUS

DOCUMENT NUMBER: 130:154980

TITLE: N,N'-Bis(6A-deoxy-β- **cyclodextrin** -6A-yl)urea as a molecular template in the formation of indigoid dyes

AUTHOR(S): Easton, Christopher J.; Harper, Jason B.; Lincoln, Stephen F.

23/04/2003<L> 20:39

CORPORATE SOURCE: Research School of Chemistry, Australian National University, Canberra, 0200, Australia
 SOURCE: New Journal of Chemistry (1998), 22(11), 1163-1165
 CODEN: NJCHE5; ISSN: 1144-0546
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The title **cyclodextrin** dimer biases competing reactions of the indoxyl anion to give indirubin and indigo against the latter, due to the preferred geometry of alignment of the **cyclodextrin** annuli. The **cyclodextrin** acts to limit the formation of indigo rather than promote the production of indirubin.

IT 130912-23-1

RL: NUU (Other use, unclassified); USES (Uses)
 (template effect on formation of indigoid dyes from indoxyl anion)

RN 130912-23-1 CAPLUS

CN β -Cyclodextrin, 6A,6'A-[(1,4-dioxo-1,4-butanediyl)diimino]bis[6A-deoxy- (9CI) (CA INDEX NAME)]

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:614302 CAPLUS

DOCUMENT NUMBER: 129:289274

TITLE: **Cyclodextrins** having natural sugar chains as side chains, their manufacture with endoglycosidase, and their intermediates

INVENTOR(S): Inazu, Toshiyuki; Yamanoi, Takashi; Mizuno, Masamori;

Matsuda, Keisuke; Haneda, Katsuji

PATENT ASSIGNEE(S): Noguchi Research Institute, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10251304	A2	19980922	JP 1997-76442	19970311
PRIORITY APPLN. INFO.:			JP 1997-76442	19970311

AB **Cyclodextrins**, whose primary OH is substituted with NH₂ and acylated by asparagine-bound glycoproteins having high-mannose or complex sugar chains, are manufactured by transglycosylation of monosaccharide-containing **cyclodextrins**, obtained by condensation of monosaccharide-containing carboxylic acids with aminocyclodextrins, in the presence of endoglycosidase. The product **cyclodextrins** are useful for drug delivery systems. Also claimed are intermediate aminocyclodextrins acylated by monosaccharide-containing carboxylic acids. (NeuAc-Gal-GlcNAc)2-(Man)3-(GlcNAc)2-Asn (NeuAc = N-acetylneuraminic acid residue; Gal = D-galactose residue; GlcNAc = N-acetyl-D-glucosamine residue; Man = D-mannose residue) was transglycosylated with Fmoc-Asn(GlcNAc)-NH- β CD (β CD = β - **cyclodextrin** residue) using endo- β -N-acetylglucosaminidase of *Mucor hiemalis* at 37° for 6

h to give 12.4% Fmoc-Asn[(NeuAc-Gal-GlcNAc)2-(Man)3-(GlcNAc)2]-NH- β CD.

IT **197509-29-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(enzymic manufacture of **cyclodextrins** having asparagine-bound sugar chains for drug delivery systems)

RN 197509-29-8 CAPLUS

CN β -Cyclodextrin, 6A-[[[(2S)-4-[[[2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]amino]-2-[[[9H-fluoren-9-ylmethoxy)carbonyl]amino]-1,4-dioxobutyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A






PAGE 2-A



PAGE 3-A



L14 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:600670 CAPLUS

DOCUMENT NUMBER: 129:302779

TITLE: Effects of solvents on the chirality of
ferrichrome-mimicking Fe³⁺ complexes based on α -
cyclodextrin

AUTHOR(S): Hori, Yuji; Tamagaki, Seizo

CORPORATE SOURCE: Dep. of Bioapplied Chemistry, Faculty of Engineering,
Osaka City University, Osaka, 558-8585, Japan


SOURCE: Nippon Kagaku Kaishi (1998), (9), 602-608

PUBLISHER: CODEN: NKAKB8; ISSN: 0369-4577

DOCUMENT TYPE: Nippon Kagakkai

LANGUAGE: Journal


GI Japanese





- AB An α -cyclodextrin-based three-fold sym. tripodal ferrichrome mimic containing three MeN(OH)COCH₂CH₂CONH side chains [I; R = NHCCH₂CH₂CON(OH)Me] was designed and synthesized. The chirality of its complex with Fe³⁺ ion was examined in various solvents such as water, methanol, and acetonitrile by using CD spectroscopy. The chirality varied remarkably with changing solvents. A mechanism involving hydrogen-bonding with solvent, which det. the chirality, was proposed.
- IT **214556-55-5DP**, complex with chromium(III) ion **214556-55-5P**
 RL: MSC (Miscellaneous); PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
 (effects of solvents on chirality of ferrichrome-mimicking Fe³⁺ complexes based on α -cyclodextrin)
- RN 214556-55-5 CAPLUS
- CN α -Cyclodextrin, 6B,6D,6F-trideoxy-6B,6D,6F-tris[[4-(hydroxymethylamino)-1,4-dioxobutyl]amino]-2A,2C,2E,3A,3C,3E,6A,6C,6E-nona-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A



PAGE 3-A




RN 214556-55-5 CAPLUS



CN α -Cyclodextrin, 6B,6D,6F-trideoxy-6B,6D,6F-tris[[4-(hydroxymethylamino)-1,4-dioxobutyl]amino]-2A,2C,2E,3A,3C,3E,6A,6C,6E-nona-O-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A



PAGE 3-A



IT 214556-59-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(effects of solvents on chirality of ferrichrome-mimicking Fe3+
complexes based on α -**cyclodextrin**)

RN 214556-59-9 CAPLUS


CN α -Cyclodextrin, 6B,6D,6F-trideoxy-2A,2C,2E,3A,3C,3E,6A,6C,6E-nona-O-
methyl-6B,6D,6F-tris[[4-[methyl(phenylmethoxy)amino]-1,4-dioxobutyl]amino]-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





L14 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:454164 CAPLUS

DOCUMENT NUMBER: 129:203163

TITLE: Synthesis and enhanced chemiluminescence of new cyclomaltooligosaccharide (**cyclodextrin**)

AUTHOR(S): -bound 6-phenylimidazo[1,2-a]pyrazin-3(7H)-one Teranishi, Katsunori; Komoda, Atsuko; Hisamatsu, Makoto; Yamada, Tetsuya

CORPORATE SOURCE: Faculty of Bioresources, Mie University, Mie, 514, Japan

SOURCE: Carbohydrate Research (1998), 306(1-2), 177-187
CODEN: CRBRAT; ISSN: 0008-6215

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In order to provide chemiluminescent substrates that have high light-emitting efficiency in aqueous solution, the structural design on 6-phenylimidazo[1,2-a]pyrazin-3(7H)-one compds. was studied in the covalent attachment of a light-producing chromophore to a cyclomaltooligosaccharide (**cyclodextrin**). The synthesis of **cyclodextrin**-bound 6-phenylimidazo[1,2-a]pyrazin-3(7H)-one compds. was achieved by the formation of an amido bond between a 6-phenylimidazo[1,2-a]pyrazin-3(7H)-one and a mono-6-amino-6-deoxycyclodextrin. The properties of oxygen-induced chemiluminescence of the synthesized **cyclodextrin**-bound light-emitting chromophores were investigated. The light-emitting efficiency in pH 8.3 phosphate buffer was remarkably dependent on the kind of bound **cyclodextrin** and the binding site between the chromophore and **cyclodextrin**. The light-emitting efficiency of a **cyclodextrin**-bound compound in which cyclomaltoheptaose (β -**cyclodextrin**) had been covalently attached to the 2-position of the imidazo[1,2-a]pyrazin-3(7H)-one ring system showed an up to 11-fold enhancement over that of a non-**cyclodextrin** chromophore, whereas attachment to cyclomaltohexaose (α -**cyclodextrin**) resulted in no enhancement. Moreover, this study indicated that the strategy that involves covalently attaching a light-producing chromophore onto a **cyclodextrin** for the enhancement of chemiluminescence is more efficient than the use of an aqueous solution containing very large amts. of **cyclodextrin**.

IT 212253-66-2P 212253-67-3P


RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(synthesis and enhanced chemiluminescence of cyclomaltooligosaccharide **cyclodextrin** bound 6-phenylimidazo[1,2-a]pyrazin-3-one)

RN 212253-66-2 CAPLUS


CN α -Cyclodextrin, 6A-deoxy-6A-[[4-[[5-(4-methoxyphenyl)pyrazinyl]amino]-1,4-dioxobutyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 212253-67-3 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[4-[[5-(4-methoxyphenyl)pyrazinyl]amino]-1,4-dioxobutyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:431175 CAPLUS

DOCUMENT NUMBER: 129:180027


TITLE: **Cyclodextrin** as Carrier of Peptide Hormones.
Conformational and Biological Properties of β -
Cyclodextrin/Gastrin Constructs


AUTHOR(S): Schaschke, Norbert; Fiori, Stella; Weyher, Elisabeth;

Escrieut, Chantal; Fourmy, Daniel; Mueller, Gerhard;
 Moroder, Luis
 CORPORATE SOURCE: Max-Planck-Institut fuer Biochemie, Martinsried,
 82152, Germany
 SOURCE: Journal of the American Chemical Society (1998),
 120(28), 7030-7038
 CODEN: JACSAT; ISSN: 0002-7863
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

- AB The C-terminal tetrapeptide amide of gastrin, the shortest sequence of this gastrointestinal hormone capable of exhibiting all the biol. properties even though at reduced potency, and the related heptapeptide amide were covalently linked to mono-(6-succinylamino-6-deoxy)- β -**cyclodextrin** to analyze the effect of the bulky cyclic carbohydrate moiety on recognition of the peptides by the G-protein-coupled CCK-B/gastrin receptor and on their signal transduction potencies. With the four-carbon succinyl spacer and particularly with the addnl. tripeptide spacer in the heptapeptide/ β -**cyclodextrin** conjugate, full recognition by the receptor was obtained with binding affinities identical to those of the unconjugated tetrapeptide and with a potency comparable to that of full agonists. Docking of this conjugate onto a structure of the human CCK-B receptor derived by homol. modeling indicates sufficient free space of the peptide moiety for intermol. interaction at the putative gastrin binding site, whereby addnl. interactions of the **cyclodextrin** with the receptor surface apparently suffice for stabilizing the complex and thus for triggering the full hormonal message. The host/guest complexation of the peptide moiety by the β -**cyclodextrin** which seems to occur at least in the case of the tetrapeptide conjugate does not suffice in its strength for competing with the receptor recognition. However, multiple presentation of the tetragastrin by its covalent linkage to the heptakis-(6-succinylamino-6-deoxy)- β -**cyclodextrin** leads to peptide/peptide and/or peptide/**cyclodextrin** collapses with strong interferences in the receptor recognition process. Retention of full agonism by suitably designed monoconjugates of bioactive peptides with **cyclodextrins** suggests a highly promising approach for targeting host/guest complexed or covalently bound cytotoxic drugs to specific tumor cells for receptor-mediated internalization.
- IT **211360-86-0P 211360-87-1P**
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (conformational and biol. properties of β -**cyclodextrin** /gastrin constructs)
- RN 211360-86-0 CAPLUS
- CN L-Phenylalaninamide, N-[4-[(6A-deoxy- β -cyclodextrin-6A-yl)amino]-1,4-dioxobutyl]-L-tryptophyl-L-norleucyl-L- α -aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 211360-87-1 CAPLUS

CN L-Phenylalaninamide, N-[4-[(6A-deoxy- β -cyclodextrin-6A-yl) amino]-1,4-dioxobutyl]-L-alanyl-L-tyrosylglycyl-L-tryptophyl-L-norleucyl-L- α -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 2-A



PAGE 3-A



PAGE 3-B

—CO₂H

REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:706269 CAPLUS

DOCUMENT NUMBER: 127:346584

TITLE: Synthesis of **cyclodextrin** derivatives

carrying bio-recognizable saccharide antennae

AUTHOR(S): Kassab, Rima; Felix, Caroline; Parrot-Lopez, Helene; Bonaly, Roger

CORPORATE SOURCE: Equipe Reconnaissance et Organisation Moleculaire et

23/04/2003<L> 20:39

Biomoleculaire, associee au CNRS Universite Claude
Bernard-Lyon I, Villeurbanne, 69622, Fr.

SOURCE:

Tetrahedron Letters (1997), 38(43), 7555-7558

CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER:

Elsevier

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB The use of coupling saccharide antenna onto **cyclodextrins** allows mobility for the biol. active galactose head group, and allows the recognition process by the lectin (KbCWL). Not. This paper reports a chem. synthesis of β -CD derivs. using spacer arms 3, 4, 5, 6 and 9 carbon atoms. Preliminary results suggested that recognition is strongly dependent on the length of the spacer chain between the **cyclodextrin** and the sugar head group.

IT 198149-56-3P 198149-57-4P 198149-58-5P

198149-59-6P 198149-60-9P

RL: SPN (Synthetic preparation); PREP (Preparation)


(synthesis of **cyclodextrin** derivs. carrying bio-recognizable saccharide antennae)


RN 198149-56-3 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[3-(β -D-galactopyranosylamino)-1,3-dioxopropyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







RN 198149-58-5 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[5-(β -D-galactopyranosylamino)-1,5-dioxopentyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 198149-59-6 CAPLUS


CN β -Cyclodextrin, 6A-deoxy-6A-[[6-(β -D-galactopyranosylamino)-1,6-dioxohexyl]amino]- (9CI) (CA INDEX NAME)




Absolute stereochemistry.







RN 198149-60-9 CAPLUS
 CN β -Cyclodextrin, 6A, 6B, 6C, 6D, 6E, 6F, 6G-heptadeoxy-6A, 6B, 6C, 6D, 6E, 6F, 6G-heptakis[[9-(β -D-galactopyranosylamino)-1,9-dioxononyl]amino] - (9CI)
 (CA INDEX NAME)








PAGE 2-B



PAGE 3-B



L14 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:686353 CAPLUS

DOCUMENT NUMBER: 127:319167

TITLE: The chemo-enzymic synthesis and evaluation of oligosaccharide-branched **cyclodextrins**

AUTHOR(S): Matsuda, Keisuke; Inazu, Toshiyuki; Haneda, Katsuji; Mizuno, Mamoru; Yamanoi, Takashi; Hattori, Kenjiro; Yamamoto, Kenji; Kumagai, Hidehiko

CORPORATE SOURCE: Tokyo Institute of Polytechnics, Faculty of Engineering, Atsugi, 243-02, Japan

SOURCE: Bioorganic & Medicinal Chemistry Letters (1997), 7(18), 2353-2356

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The syntheses of oligosaccharide-branched **cyclodextrins**, which showed potential binding to the saccharide-interacting protein, lectin, were investigated. The trans-glycosidations to Fmoc-Asn(GlcNAc)-NH-**cyclodextrin** by endo- β -N-acetylglucosaminidase of *Mucor hiemalis* (Endo-M) gave three kinds of natural oligosaccharide-branched **cyclodextrins** in satisfactory yields. The association constant of the high-mannose type oligosaccharide-branched CD with immobilized Con A was found to be approx. 1.6×10^7 M⁻¹ using an optical biosensor.

IT 197509-30-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(chemo-enzymic preparation oligosaccharide-branched **cyclodextrins** and their binding to proteins and lectins)


RN 197509-30-1 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[(2S)-4-[[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]amino]-2-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-1,4-dioxobutyl]amino]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B





PAGE 2-A

PAGE 2-B



IT 197509-29-8P



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(chemo-enzymic preparation oligosaccharide-branched **cyclodextrins** and their binding to proteins and lectins)

RN 197509-29-8 CAPLUS


CN β -Cyclodextrin, 6A-[[(2S)-4-[[2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]amino]-2-[[(9H-fluoren-9-ylmethoxy) carbonyl]amino]-1,4-dioxobutyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






IT **197509-30-1DP, Con A complex 197509-31-2P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (chemo-enzymic preparation oligosaccharide-branched **cyclodextrins**
 and their binding to proteins and lectins)
 RN 197509-30-1 CAPLUS
 CN β -Cyclodextrin, 6A-deoxy-6A-[[[(2S)-4-[[O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[α -D-mannopyranosyl-(1 \rightarrow 6)]-O- α -D-mannopyranosyl-(1 \rightarrow 6)-O-[O- α -D-mannopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 3)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]amino]-2-[[[(9H-fluoren-9-ylmethoxy) carbonyl]amino]-1,4-dioxobutyl]amino]- (9CI)
 (CA INDEX NAME)









RN 197509-31-2 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[(2S)-4-[[O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)-O- α -D-mannopyranosyl-(1 \rightarrow 3)-O-[O- β -D-galactopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 2)- α -D-mannopyranosyl-(1 \rightarrow 6)]-O- β -D-mannopyranosyl-(1 \rightarrow 4)-O-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl-(1 \rightarrow 4)-2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]amino]-2-[[(9H-fluoren-9-ylmethoxy) carbonyl] amino]-1,4-dioxobutyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




PAGE 2-A



HO—

HO—

PAGE 2-B



L14 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1997:175577 CAPLUS
 DOCUMENT NUMBER: 126:277686
 TITLE: A versatile synthesis of linked **cyclodextrins**
 AUTHOR(S): Easton, Christopher J.; van Eyk, Steven J.; Lincoln, Stephe F.; May, Bruce L.; Papageorgiou, John; Williams, Michael L.
 CORPORATE SOURCE: Res. Sch. Chem., Australian National Univ., Canberra, 0200, Australia
 SOURCE: Australian Journal of Chemistry (1997), 50(1), 9-12
 CODEN: AJCHAS; ISSN: 0004-9425
 PUBLISHER: Commonwealth Scientific and Industrial Research Organization
 DOCUMENT TYPE: Journal

LANGUAGE:

English

AB Reactions of amino-substituted **cyclodextrins** with bis(3-nitrophenyl) oxalate, malonate, succinate and glutarate, and with di-Ph carbonate, afford a range of linked **cyclodextrins**. These include α - and β - **cyclodextrin** dimers, joined by substitution at either C6 or C3, and asym. species with a β - **cyclodextrin** bonded to an α - **cyclodextrin** and a C3-substituted **cyclodextrin** attached to a C6-substituted moiety.

IT 130912-22-0P 130912-23-1P 130912-24-2P
138166-05-9P 180297-25-0P 188947-69-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of linked **cyclodextrins**)

RN 130912-22-0 CAPLUS
CN α -Cyclodextrin, 6A,6'A-[(1,4-dioxo-1,4-butanediyl)diimino]bis[6A-deoxy- (9CI) (CA INDEX NAME)]

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 130912-23-1 CAPLUS


CN β -Cyclodextrin, 6A,6'A-[(1,4-dioxo-1,4-butanediyl)diimino]bis[6A-deoxy- (9CI) (CA INDEX NAME)]

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 130912-24-2 CAPLUS

CN β -Cyclodextrin, 6A,6'A-[(1,5-dioxo-1,5-pentanediy)diimino]bis[6A-deoxy- (9CI) (CA INDEX NAME)]


PAGE 1-A



PAGE 2-A



PAGE 3-A



RN 138166-05-9 CAPLUS


CN β -Cyclodextrin, 6A-deoxy-6A-[[4-[(6A-deoxy- α -cyclodextrin-6A-yl)amino]-1,4-dioxobutyl]amino]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 180297-25-0 CAPLUS


CN β -Cyclodextrin, 6A,6'A-[(1,3-dioxo-1,3-propanediyl)diimino]bis[6A-deoxy- (9CI) (CA INDEX NAME)]

PAGE 1-A





PAGE 2-A





RN 188947-69-5 CAPLUS
 CN β -Cyclodextrin, 3A-deoxy-3A-[[4-[(6A-deoxy- β -cyclodextrin-6A-yl)amino]-1,4-dioxobutyl]amino]-, (2AS,3AS)- (9CI) (CA INDEX NAME)



HO-CH₂CH₂
|
R

L14 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1997:123417 CAPLUS
 DOCUMENT NUMBER: 126:225465
 TITLE: Complexation of methyl orange and Tropaeolin 000 Number 2
 by β -cyclodextrin dimers
 AUTHOR(S): Haskard, Carolyn A.; May, Bruce L.; Kurucsev, Tomas;
 Lincoln, Stephen F.; Easton, Christopher J.
 CORPORATE SOURCE: Department of Chemistry, University of Adelaide, South
 Australia, 5005, Australia
 SOURCE: Journal of the Chemical Society, Faraday Transactions
 (1997), 93(2), 279-282
 CODEN: JCFTEV; ISSN: 0956-5000
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Spectrophotometric studies of the complexation of Methyl orange (MO-) and Tropaeolin 000 Number 2 (TR-) anions by dimeric N,N'-bis(6A-deoxy-6A- β -**cyclodextrin**)urea (β CD)2ur and its oxalamide and succinamide analogs, (β CD)2ox and (β CD)2su, resp., are consistent with the predominant formation of complexes of the general formulas (β CD)2x·MO- characterized by stability consts. $K_1 = (1.05 \pm 0.04) + 105$, $(1.92 \pm 0.04) + 105$ and $(2.50 \pm 0.02) + 104$ dm³ mol⁻¹ and (β CD)2x·TR- characterized by $K_1 = (1.39 \pm 0.03) + 104$, $(7.4 \pm 0.1) + 103$ and $(4.60 \pm 0.05) + 103$ dm³ mol⁻¹, in aqueous phosphate buffer at pH 9.0 and 5.5 and 298.2 K. These values are significantly greater than $K_1 = 2160$ and 710 dm³ mol⁻¹ for the β -**cyclodextrin** complexes, β CD·MO- and β CD·TR- and are indicative of cooperative binding in (β CD)2x·MO- and (β CD)2x·TR-. The factors affecting complex stability are discussed and comparisons are made with related systems.

IT 188357-80-4P 188358-73-8P 188358-75-0P
188358-77-2P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(inclusion complexation of methyl orange and tropaeolin by β -**cyclodextrin** dimers)

RN 188357-80-4 CAPLUS

CN β -Cyclodextrin, 6A,6'A-[(1,4-dioxo-1,4-butanediyl)diimino]bis[6A-deoxy-, compd. with sodium 4-[[4-(dimethylamino)phenyl]azo]benzenesulfonate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 130912-23-1


CMF C88 H144 N2 O70

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 547-58-0

CMF C14 H15 N3 O3 S . Na



● Na

RN 188358-73-8 CAPLUS

CN β -Cyclodextrin, 6A,6'A-[(1,4-dioxo-1,4-butanediyl)diimino]bis[6A-deoxy-, compd. with 4-[(2-hydroxy-1-naphthalenyl)azo]benzenesulfonic acid monosodium salt (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 130912-23-1


CMF C88 H144 N2 O70

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 633-96-5

CMF C16 H12 N2 O4 S . Na



● Na

RN 188358-75-0 CAPLUS

CN β-Cyclodextrin, 6A,6'A-[(1,4-dioxo-1,4-butanediyl)diimino]bis[6A-deoxy-, compd. with 4-[(2-hydroxy-1-naphthalenyl)azo]benzenesulfonic acid monosodium salt (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 130912-23-1


CMF C88 H144 N2 O70

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 633-96-5

CMF C16 H12 N2 O4 S . Na



● Na

RN 188358-77-2 CAPLUS
 CN β -Cyclodextrin, 6A,6'A-[(1,4-dioxo-1,4-butanediyl)diimino]bis[6A-deoxy-, compd. with 6-[(4-methylphenyl)amino]-2-naphthalenesulfonic acid monosodium salt (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 130912-23-1
 CMF C88 H144 N2 O70

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 53313-85-2
 CMF C17 H15 N O3 S . Na



● Na

L14 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:491249 CAPLUS

DOCUMENT NUMBER: 125:215415

TITLE:

Cyclodextrins as templates for the presentation of protease inhibitors

AUTHOR(S):

Schaschke, N.; Musiol, H.-J.; Assfalg-Machleidt, I.; Machleidt, W.; Rudolph-Boehner, S.; Moroder, L.

CORPORATE SOURCE:

Max-Planck-Institut fuer Biochemie, AG Bioorganische

Chemie, Am Klopferspitz 18A, Martinsried, 82152,
Germany
SOURCE: FEBS Letters (1996), 391(3), 297-301
CODEN: FEBLAL; ISSN: 0014-5793
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 125:215415

AB Mono(6-succinylamido-6-deoxy)- β - **cyclodextrin** was synthesized by classical carbohydrate chem. and used as a template mono-functionalized with the linear, fully flexible 4C-spacer carboxylate for covalent linkage of the calpain inhibitor leucyl-leucyl-norleucinal. Spectroscopic analyses of the conjugate do not support a self-inclusion of part of the hydrophobic peptide tail, but confirm its intra-or intermol. interaction with the template moiety that leads to full water solubility. The inhibitory potency of the β - **cyclodextrin**/peptide aldehyde construct was compared with that of the parent Ac-Leu-Leu-Nle-H against cathepsin B and calpain. Despite the large size of the template the inhibition of cathepsin B was only slightly reduced in full agreement with the X-ray structure of this enzyme which shows full accessibility of the S-subsites. For this enzyme the 4C-spacer is apparently sufficient to guarantee optimal interaction of the peptide tail with the binding cleft. Conversely, for μ -calpain a significantly decreased inhibitory potency was obtained with the conjugate suggesting steric interference of the template in the binding process. These results show that the beneficial properties of the **cyclodextrin** template can be retained in conjugates with bioactive peptides if attention is paid to optimize in each case the size and nature of the spacer for optimal recognition of the grafted biomol.

IT 181487-21-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of **cyclodextrin** conjugates for presentation of protease inhibitors)

RN 181487-21-8 CAPLUS

CN L-Norleucine, N-[N-[N-[4-[(6A-deoxy- β -cyclodextrin-6A-yl)amino]-1,4-dioxobutyl]-L-leucyl]-L-leucyl]- (9CI) (CA INDEX NAME)

CORPORATE SOURCE: Bruce L.; Lincoln, Stephen F.
Department of Chemistry, University of Adelaide, 5005,
Australia

SOURCE: Journal of Physical Chemistry (1996), 100(34),
14457-14461
CODEN: JPCHAX; ISSN: 0022-3654

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A fluorimetric study shows that 6-(p-toluidinyl)naphthalene-2-sulfonate (TNS-) forms binary complexes with dimeric N,N'-bis(6A-deoxy-6A-**β-cyclodextrin**)glutaramide and its succinamide, malonamide, oxalamide, and urea analogs characterized by stability consts. $13\ 010 \pm 20$, $16\ 700 \pm 20$, $11\ 000 \pm 10$, $32\ 640 \pm 90$, and $45\ 230 \pm 70\ \text{dm}^3\ \text{mol}^{-1}$, resp., in aqueous phosphate buffer at pH 7.0, $I = 0.10\ \text{dm}^3\ \text{mol}^{-1}$ and 298.2 K. These values are substantially greater than that for the **β-cyclodextrin**·TNS- complex and are indicative of collaborative binding in the **β-cyclodextrin** dimer complexes. The factors affecting the stabilities of the **cyclodextrin** dimer complexes and their fluorescence characteristics are discussed, and comparisons are made with related systems.

IT **180297-26-1 180469-39-0 180469-40-3**
RL: PRP (Properties)
(stability consts. for binary complexes of dimer **β-cyclodextrins** with 6-(p-toluidinyl)naphthalene-2-sulfonate in aqueous phosphate buffer)



RN 180297-26-1 CAPLUS


CN **β-Cyclodextrin, 6A,6'A-[(1,3-dioxo-1,3-propanediyl)diimino]bis[6A-deoxy-, compd. with 6-[(4-methylphenyl)amino]-2-naphthalenesulfonic acid ion(1-) (1:1) (9CI) (CA INDEX NAME)**

CM 1

CRN 180297-25-0

CMF C87 H142 N2 O70






CM 2

CRN 20096-84-8

CMF C17 H14 N O3 S





RN 180469-39-0 CAPLUS


CN β -Cyclodextrin, 6A,6'A-[(1,5-dioxo-1,5-pentanediyldiimino]bis[6A-deoxy-, compd. with 6-[(4-methylphenyl)amino]-2-naphthalenesulfonic acid ion(1-) (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 130912-24-2

CMF C89 H146 N2 O70






CM 2

CRN 20096-84-8

CMF C17 H14 N O3 S



RN 180469-40-3 CAPLUS

CN β -Cyclodextrin, 6A,6'A-[(1,4-dioxo-1,4-butanediyl)diimino]bis[6A-deoxy-, compd. with 6-[(4-methylphenyl)amino]-2-naphthalenesulfonic acid ion(1-) (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 130912-23-1


CMF C88 H144 N2 O70

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 20096-84-8

CMF C17 H14 N O3 S



L14 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:752253 CAPLUS
 DOCUMENT NUMBER: 123:218332

23/04/2003<L> 20:39

TITLE: Reduction of the hemolytic effect in a biologically recognizable β - **cyclodextrin**

AUTHOR(S): Leray, E.; Leroy-Lechat, F.; Parrot-Lopez, H.; Duchene, D.

CORPORATE SOURCE: 1"Groupe Cyclodextrines Amphiphiles", BIOCIS, Villeurbanne, FG9622, Fr.

SOURCE: Supramolecular Chemistry (1995), 5(2), 149-51
CODEN: SCHEER; ISSN: 1061-0278

PUBLISHER: Gordon & Breach

DOCUMENT TYPE: Journal

LANGUAGE: English


AB β - **Cyclodextrin** derivs. having azido, amino and bioactive galactosylamido spacer functions were tested for hemolytic effect and compared with that of hydroxypropyl- β - **cyclodextrin**. The **cyclodextrin** coupled to the bioactive saccharide galactose via a spacer and which has bio-recognition properties for cell-wall lectin shows an extremely reduced hemolytic effect.


IT **156769-72-1**
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reduction of the hemolytic effect of β - **cyclodextrin** derivs.)

RN **156769-72-1** CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[9-(β -D-galactopyranosylamino)-1,9-dioxononyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A





L14 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:645724 CAPLUS

DOCUMENT NUMBER: 123:102013

TITLE: Recognition ability and cytotoxicity of some oligosaccharidyl substituted β -cyclodextrins

AUTHOR(S): Attioui, Fatima; Al-Omar, Anouar; Leray, Eric; Parrot-Lopez, Helene; Finance, Chantal; Bonaly, Roger
CORPORATE SOURCE: Faculte des Sciences Pharmaceutiques et Biologiques, Universite Henri Poincare Nancy 1, Nancy, 54001, Fr.
SOURCE: Biology of the Cell (1994), 82(2-3), 161-7
CODEN: BCELDF; ISSN: 0248-4900

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB This paper reports a chemico-enzymic synthesis of β -CD derivs. The recognition properties of these derivs. were tested using flocculating yeast and isolated lectins. It was observed that the substitution of β -cyclodextrins with galactose end arms induces the better recognition by a cell-linked galactose-specific lectin. The physicochem. effects of the β -CD derivs. on membranes were evaporating using red blood cells and the effects on the viability of yeast and human rectal tumor cells were appreciated by measuring the mitochondrial dehydrogenase activity. The substitutions of the β -CD ring by sugar antennae decrease the neg. physicochem. effects of the β -CD, ie their hemolytic properties. However, these substitutions induce significant modifications of the biol. properties of the mols., particularly the cytotoxicity and the growth of eukaryotic cells.


IT 156769-72-1 162425-01-6 166178-79-6

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)


(recognition ability and cytotoxicity of oligosaccharidyl substituted

β- cyclodextrins)
 RN 156769-72-1 CAPLUS
 CN β-Cyclodextrin, 6A-deoxy-6A-[[9-(β-D-galactopyranosylamino)-1,9-dioxononyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 162425-01-6 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[9-[(6-deoxy- β -L-galactopyranosyl)amino]-1,9-dioxononyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 166178-79-6 CAPLUS
 CN β -Cyclodextrin, 6A,6B-bis[[9-[[2-(acetylamino)-2-deoxy- β -D-glucopyranosyl]amino]-1,9-dioxononyl]amino]-6A,6B-dideoxy- (9CI) (CA INDEX NAME)

PAGE 1-A





* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

L14 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:567871 CAPLUS

DOCUMENT NUMBER: 123:286424

TITLE: Remarkable molecular recognition of dansyl-modified **cyclodextrin** dimer

AUTHOR(S): Nakamura, Michiei; Ikeda, Tsukasa; Nakamura, Asao; Ikeda, Hiroshi; Ueno, Akihiko; Toda, Fujio

CORPORATE SOURCE: Dep. Bioeng., Tokyo Inst. Technol., Yokohama, 226, Japan

SOURCE: Chemistry Letters (1995), (5), 343-4

CODEN: CMLTAG; ISSN: 0366-7022

PUBLISHER: Nippon Kagakkai

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Dansyl-modified β - **cyclodextrin** dimer changes fluorescence intensity depending on the mol. species in aqueous solution and exhibits remarkable mol. recognition for steroidal compds.

IT 169062-02-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(inclusion reaction of dansyl-modified **cyclodextrin** dimer
with steroids)

RN 169062-02-6 CAPLUS

CN β -Cyclodextrin, 6A,6'A-[[2-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]-1,4-dioxo-1,4-butanediyl]diimino]bis[6A-deoxy-, (S)- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 169438-31-7P 169438-32-8P 169438-33-9P
169438-34-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(inclusion reaction of dansyl-modified **cyclodextrin** dimer
with steroids)

RN 169438-31-7 CAPLUS

CN Cholan-24-oic acid, 3,7-dihydroxy-, (3 α ,5 β ,7 β)-, compd.
with 6A,6'A-[[2-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]-1,4-dioxo-1,4-butanediyl]diimino]bis[6A-deoxy- β -cyclodextrin] (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 169062-02-6

CMF C100 H156 N4 O72 S


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 128-13-2

CMF C24 H40 O4

Absolute stereochemistry.



RN 169438-32-8 CAPLUS

CN Cholan-24-oic acid, 3,12-dihydroxy-, (3 α ,5 β ,12 α)-, compd.
with 6A,6'A-[[2-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]-1,4-dioxo-1,4-butanediyl]diimino]bis[6A-deoxy- β -cyclodextrin] (1:1) (9CI)
(CA INDEX NAME)

CM 1

CRN 169062-02-6

CMF C100 H156 N4 O72 S


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 83-44-3

CMF C24 H40 O4

Absolute stereochemistry.



RN 169438-33-9 CAPLUS

CN Cholan-24-oic acid, 3,7,12-trihydroxy-, (3 α ,5 β ,7 α ,12.α
a.)-, compd. with 6A,6'A-[[2-[[[5-(dimethylamino)-1-
naphthalenyl]sulfonyl]amino]-1,4-dioxo-1,4-butanediyl]diimino]bis[6A-deoxy-
β-cyclodextrin] (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 169062-02-6

CMF C100 H156 N4 O72 S


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 81-25-4

CMF C24 H40 O5

Absolute stereochemistry.



RN 169438-34-0 CAPLUS
 CN Cholan-24-oic acid, 3,7-dihydroxy-, (3 α ,5 β ,7 α)-, compd.
 with 6A,6'A-[[2-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]-1,4-
 dioxo-1,4-butanediyl]diimino]bis[6A-deoxy- β -cyclodextrin] (1:1) (9CI)
 (CA INDEX NAME)

CM 1


CRN 169062-02-6
 CMF C100 H156 N4 O72 S

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 474-25-9
 CMF C24 H40 O4

Absolute stereochemistry.




L14 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:38514 CAPLUS
 DOCUMENT NUMBER: 122:240200
 TITLE: New β - **cyclodextrin** derivatives
 possessing biologically active saccharide antennae
 AUTHOR(S): Parrot-Lopez, Helene; Leray, Eric; Coleman, Anthony W.
 CORPORATE SOURCE: "Groupe Cyclodextrines Amphiphiles", Universite de
 Paris XI, Chatenay-Malabry, F92296, Fr.
 SOURCE: Supramolecular Chemistry (1993), 3(1), 37-42
 CODEN: SCHEER; ISSN: 1061-0278
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The synthesis of monosubstituted β - **cyclodextrin** derivs.
 having the monosaccharides, β -D-glucose, β -D-galactose,
 α -D-mannose, β -L and β -D-fucose linked to the macrocycle
 via a C9 spacer chain is described. The approach is based on the highly
 efficient coupling of the isothiocyanate sugar to monomethyl
 nonandedicarboxylate to generate a stable amido linkage. The NMR studies
 show the saccharide antennae to be oriented into the environment and not
 towards the CD cavity.
 IT 156769-72-1P 162265-61-4P 162424-98-8P
 162425-01-6P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn of β - **cyclodextrin** derivs. possessing biol. active
 saccharide antennae)

RN 156769-72-1 CAPLUS


CN β -Cyclodextrin, 6A-deoxy-6A-[[9-(β -D-galactopyranosylamino)-1,9-
 dioxononyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A








RN 162265-61-4 CAPLUS
 CN β -Cyclodextrin, 6A-deoxy-6A-[[9-[(6-deoxy- β -D-galactopyranosyl)amino]-1,9-dioxononyl]amino]- (9CI) (CA INDEX NAME)



PAGE 2-A



RN 162424-98-8 CAPLUS
 CN β -Cyclodextrin, 6A-deoxy-6A-[[9-(α -D-mannopyranosylamino)-1,9-dioxononyl]amino]- (9CI) (CA INDEX NAME)





RN 162425-01-6 CAPLUS

23/04/2003<L> 20:39

CN β -Cyclodextrin, 6A-deoxy-6A-[[9-[(6-deoxy- β -L-galactopyranosyl)amino]-1,9-dioxononyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A





L14 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:491607 CAPLUS

DOCUMENT NUMBER: 121:91607

TITLE: Synthesis of new oligosaccharide-thio- β -**cyclodextrins** (CDS): a novel family of potent drug-targetting vectors

AUTHOR(S): de Robertis, Laurence; Lancelon-Pin, Christine; Driguez, Hugues; Attiou, Fatima; Bonaly, Roger; Marsura, Alain

CORPORATE SOURCE: CERMAV, CNRS, Grenoble, 38041, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (1994), 4(9), 1127-30

CODEN: BMCLE8; ISSN: 0960-894X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Six potential carriers incorporating one or more thio-D-galactosyl residue(s) linked to β - **cyclodextrin** as complexing tool, were prepared and evaluated in vitro for their specific recognition towards a cell wall galactose specific lectin (KbCWL). The inhibition of yeast flocculation by the compds. was compared to reference compds., p-nitrophenyl-galactose or disaccharides containing an α or β -galactose non reducing terminal unit. The heptakisgalactosyl-CD derivs. were the most efficient compds.



IT 156769-72-1

RL: PROC (Process)

(drug carrier properties and lectin binding of)

RN 156769-72-1 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[9-(β -D-galactopyranosylamino)-1,9-dioxononylamino]- (9CI) (CA INDEX NAME)



L14 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:409838 CAPLUS
DOCUMENT NUMBER: 121:9838

TITLE: Synthesis of **cyclodextrin** heterodimer having α - and β - **cyclodextrin** units and its cooperative and site-specific binding

AUTHOR(S): Wang, Yong; Ueno, Akihiko; Toda, Fujio

CORPORATE SOURCE: Fac. Biosci. Biotechnol., Tokyo Inst. Technol., Yokohama, 227, Japan

SOURCE: Chemistry Letters (1994), (1), 167-70
CODEN: CMLTAG; ISSN: 0366-7022

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A **cyclodextrin** heterodimer, which has α - and β - **cyclodextrin** units as two different receptor sites, was prepared It showed cooperative and site-specific binding to isoamyl p-dimethylaminobenzoate with the alkyl group included in the β - **cyclodextrin** cavity while dimethylaminobezene moiety partially included in the α - **cyclodextrin** cavity. This binding mode was substantiated by the fact the TICT emission of this guest is greatly enhanced by the **cyclodextrin** heterodimer.

IT 155750-47-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and fluorescence emission spectra of)

RN 155750-47-3 CAPLUS


CN β -Cyclodextrin, 6A-deoxy-6A-[[3-[(6A-deoxy- α -cyclodextrin-6A-yl)amino]-1,3-dioxopropyl]amino]-, compd. with 3-methylbutyl 4-(dimethylamino)benzoate (1:1) (9CI) (CA INDEX NAME)




CM 1

CRN 155688-28-1

CMF C81 H132 N2 O65


PAGE 1-A





CM 2

CRN 21245-01-2
CMF C14 H21 N O2



IT 155688-28-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)




(preparation and inclusion reaction of, with isoamyl p-dimethylaminobenzoate)

RN 155688-28-1 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[3-[(6A-deoxy- α -cyclodextrin-6A-yl)amino]-1,3-dioxopropyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A





IT 155750-48-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 155750-48-4 CAPLUS

CN β-Cyclodextrin, 6A-deoxy-6A-[[3-[(6A-deoxy-α-cyclodextrin-6A-


yl)amino]-1,3-dioxopropyl]amino]-, compd. with 2-butoxyethyl
4-(dimethylamino)benzoate (1:1) (9CI) (CA INDEX NAME)




CM 1

CRN 155688-28-1

CMF C81 H132 N2 O65


PAGE 1-A





CM 2

CRN 67362-76-9
CMF C15 H23 N O3



L14 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:62264 CAPLUS

DOCUMENT NUMBER: 120:62264

TITLE: **Cyclodextrin** derivative preparation, and formulated drugs of inclusion complexes of Propofol or Alfaxalone with the modified **cyclodextrins**

INVENTOR(S): Palmer, Clive Frederick; Ho, Paul Chi Cui; Brown, Susan Elisabeth; May, Bruce Lindley; Schiesser, Deborah Susanne; Luo, Yin; Dennis, Nicholas; Lincoln, Stephen Frederick; Coates, John Hewlett; et al.

PATENT ASSIGNEE(S): Australian Commercial Research and Development Ltd., Australia

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9317711	A1	19930916	WO 1993-AU100	19930309
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9336241	A1	19931005	AU 1993-36241	19930309
EP 630261	A1	19941228	EP 1993-905115	19930309
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:				
			AU 1992-1288	19920311
			AU 1992-1915	19920415
			AU 1992-2182	19920429
			AU 1992-3612	19920720
			AU 1992-3673	19920723
			AU 1992-3674	19920723
			AU 1992-3836	19920731
			AU 1992-4119	19920817
			AU 1992-4409	19920831
			AU 1992-4747	19920917
			AU 1993-7061	19930202
			WO 1993-AU100	19930309

OTHER SOURCE(S): MARPAT 120:62264

AB Inclusion complexes are disclosed which comprise Propofol or Alfaxalone (I) and a **cyclodextrin** derivative. The inclusion complexes increase the solubility of these 2 anesthetics. Preparation of the cyclodextrin derivs. is

included. The solubility of I in 10.04% 6A-amino-6A-N-(4-aminobutyl)-6A-deoxy- β -cyclodextrin (II) (preparation given) was 13.4 mg/mL (the solubility of I in water is 3.6 μ g/mL). No precipitation was observed when the solution was stored refrigerated overnight. When the I-II solution was injected i.p. in rats, an anesthetic effect was observed

IT **138141-90-9**


RL: BIOL (Biological study)

(acid dissociation consts. for)

RN 138141-90-9 CAPLUS


CN β -Cyclodextrin, 6A-[[4-[[2-[bis(2-aminoethyl)amino]ethyl]amino]-1,4-dioxobutyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



HO—

HO—




IT **152045-95-9p**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, for **cyclodextrin** derivative preparation for increasing solubility of Alfaxalone or Propofol)

RN 152045-95-9 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[1,4-dioxo-4-(phenylamino)butyl]amino]- (9CI) (CA INDEX NAME)



L14 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:574166 CAPLUS

DOCUMENT NUMBER: 119:174166

TITLE: Preparation of anti-retroviral **cyclodextrin** polysulfate esters

INVENTOR(S): Moriya, Tamon; Kurita, Hiroki; Otake, Toru; Mori, Haruyo; Morimoto, Motoko

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 14 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04309502	A2	19921102	JP 1991-164079	19910408
PRIORITY APPLN. INFO.:			JP 1991-164079	19910408

OTHER SOURCE(S): MARPAT 119:174166

AB The title esters contain ≥ 1 glycosyl unit having deoxyamino group on C-6 position which is derived from amino acids, and multiple sulfate ester groups or salts thereof, and are prepared Heating mono[6-(N- α -benzyloxycarbonyltryptophyl)amino-6-deoxy]- β -**cyclodextrin** in pyridine (Py) while stirring with SO₃-Py complex at 100° gave the desired polysulfate ester.

IT 150213-93-7P 150213-94-8P 150213-95-9P
150213-96-0P 150266-07-2P 150319-88-3P
150319-89-4P 150319-90-7P 150319-91-8P
150338-98-0P


RL: PREP (Preparation)



(anti-retroviral, manufacture of)

RN 150213-93-7 CAPLUS

CN β -Cyclodextrin, 6A-[[4-[[5-[bis[2-[(4-methoxyphenyl)amino]-2-oxoethyl]amino]-6-[(4-methoxyphenyl)amino]-6-oxohexyl]amino]-1,4-dioxobutyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)


PAGE 1-A







HO—

HO—





RN 150213-94-8 CAPLUS
 CN β -Cyclodextrin, 6A-[[4-[[3-[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]-1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-oxopropyl]amino]-1,4-dioxobutyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)







HO—

HO—



RN 150213-95-9 CAPLUS
 CN β -Cyclodextrin, 6A-[[4-[[3-[(1-carboxy-2-phenylethyl)amino]-1-[[(1-carboxy-2-phenylethyl)amino]carbonyl]-3-oxopropyl]amino]-1,4-dioxobutyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)




PAGE 2-A

HO—



HO—

PAGE 2-B



RN 150213-96-0 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[4-[[[3-[[2-methoxy-2-oxo-1-(phenylmethyl)ethyl]amino]-1-[[[2-methoxy-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-oxopropyl]amino]-1,4-dioxobutyl]amino]- (9CI) (CA INDEX NAME)




PAGE 2-A


HO—

HO—



PAGE 2-B




PAGE 3-A



RN 150266-07-2 CAPLUS
 CN β-Cyclodextrin, 6A,6?-bis[[4-amino-2-[(4-chlorobenzoyl)amino]-1,4-dioxobutyl]amino]-6A,6?-dideoxy-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)





5 (D1-OH)


RN 150319-88-3 CAPLUS



CN β -Cyclodextrin, 6A-[[4-[[5-[bis[2-[(4-methoxyphenyl)amino]-2-oxoethyl]amino]-6-[(4-methoxyphenyl)amino]-6-oxohexyl]amino]-1,4-dioxobutyl]amino]-6A-deoxy-, octadecakis(hydrogen sulfate) (ester), octadecapotassium salt (9CI) (CA INDEX NAME)

CM 1

CRN 150213-93-7


CMF C77 H112 N6 O42





HO—


HO—



CM 2

CRN 7664-93-9

CMF H2 O4 S





RN 150319-89-4 CAPLUS

CN β -Cyclodextrin, 6A-[[4-[[3-[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]-1-[[[2-amino-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-oxopropyl]amino]-1,4-dioxobutyl]amino]-6A-deoxy-, nonadecakis(hydrogen sulfate) (ester), nonadecapotassium salt (9CI) (CA INDEX NAME)

CM 1

CRN 150213-94-8

CMF C68 H100 N6 O40




PAGE 2-A


HO—

HO—

PAGE 2-B




PAGE 3-A



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 150319-90-7 CAPLUS


CN β -Cyclodextrin, 6A-[[4-[[3-[(1-carboxy-2-phenylethyl)amino]-1-[[[(1-carboxy-2-phenylethyl)amino]carbonyl]-3-oxopropyl]amino]-1,4-dioxobutyl]amino]-6A-deoxy-, octadecakis(hydrogen sulfate) (ester), octadecapotassium salt (9CI) (CA INDEX NAME)

CM 1


CRN 150213-95-9

CMF C68 H98 N4 O42

PAGE 1-A




PAGE 1-B



PAGE 2-A

HO—


HO—



CM 2

CRN 7664-93-9

CMF H2 O4 S





RN 150319-91-8 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[4-[[3-[[2-methoxy-2-oxo-1-(phenylmethyl)ethyl]amino]-1-[[[2-methoxy-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]-3-oxopropyl]amino]-1,4-dioxobutyl]amino]-, nonadecakis(hydrogen sulfate) (ester), nonadecapotassium salt (9CI) (CA INDEX NAME)

CM 1

CRN 150213-96-0

CMF C70 H102 N4 O42




PAGE 2-A


HO—

HO—

PAGE 2-B




PAGE 3-A



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 150338-98-0 CAPLUS
 CN β -Cyclodextrin, 6A,6?-bis[[4-amino-2-[(4-chlorobenzoyl)amino]-1,4-dioxobutyl]amino]-6A,6?-dideoxy-, heptadecakis(hydrogen sulfate) (ester), heptadecapotassium salt, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


CM 1

CRN 150266-07-2
 CMF C64 H90 Cl2 N6 O39
 CCI IDS


PAGE 1-A



PAGE 2-A



PAGE 3-A




5 (D1-OH)

CM 2

CRN 7664-93-9

CMF H2 O4 S



L14 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:429142 CAPLUS

DOCUMENT NUMBER: 117:29142

TITLE: **Cyclodextrin** compositions for pharmaceutical and industrial applications

INVENTOR(S): Coates, John Hewlett; Easton, Christopher John; Lincoln, Stephen Frederick; Van Eyk, Stephen John; May, Bruce Lindley; Williams, Michael Lloyd; Brown, Susan Elizabeth; Lepore, Angelo; Liao, Ming Long; et al.

PATENT ASSIGNEE(S): Australian Commercial Research and Development Ltd., Australia

SOURCE: PCT Int. Appl., 179 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9113100	A1	19910905	WO 1991-AU71	19910301
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, PL, RO, SD, SE, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
AU 9174531	A1	19910918	AU 1991-74531	19910301
EP 518930	A1	19921223	EP 1991-905452	19910301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ES 2036504	A6	19930516	ES 1991-50026	19911031
PRIORITY APPLN. INFO.:			AU 1990-8899	19900302
			AU 1990-8993	19900308
			AU 1990-9344	19900328
			AU 1990-9373	19900329
			AU 1990-9756	19900423
			AU 1990-1538	19900803
			AU 1990-1755	19900816
			AU 1990-2269	19900912
			AU 1990-3596	19901129
			AU 1990-3624	19901130
			AU 1991-4284	19910121
			AU 1991-4603	19910214
			AU 1991-4856	19910227
			WO 1991-AU71	19910301
AB	Cyclodextrin derivs. forming soluble, stable inclusion complexes and covalent compds. with drugs, agrochems., etc. are prepared An α - cyclodextrin 6-tosylate was treated with NaN ₃ , hydrogenated to the 6-amino-6-deoxy derivative, and condensed with ibuprofen to give a drug for ibuprofen delivery. The cyclodextrin derivs. and their inclusion complexes can also be used for the chromatog. separation of enantiomers from racemic mixts.			
IT	130912-22-0P 130912-24-2P 138141-88-5P 138166-05-9P			
	RL: PREP (Preparation)			
	(preparation of, in manufacture of drug delivery system)			
RN	130912-22-0 CAPLUS			
CN	α -Cyclodextrin, 6A,6'A-[(1,4-dioxo-1,4-butanediyl)diimino]bis[6A-			


deoxy- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 130912-24-2 CAPLUS

CN β -Cyclodextrin, 6A,6'A-[(1,5-dioxo-1,5-pentanediy1)diimino]bis[6A-deoxy- (9CI) (CA INDEX NAME)]


PAGE 1-A



PAGE 2-A




PAGE 3-A



RN 138141-88-5 CAPLUS

CN β -Cyclodextrin, 6A-[(4-amino-1,4-dioxobutyl)amino]-6A-deoxy- (9CI)
(CA INDEX NAME)



RN 138166-05-9 CAPLUS

CN β -Cyclodextrin, 6A-deoxy-6A-[[4-[(6A-deoxy- α -cyclodextrin-6A-yl)amino]-1,4-dioxobutyl]amino]- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **138141-90-9P 138166-06-0P**


RL: PREP (Preparation)

(preparation of, in manufacture of drug delivery systems)

RN 138141-90-9 CAPLUS


CN β -Cyclodextrin, 6A-[[4-[[2-[bis(2-aminoethyl)amino]ethyl]amino]-1,4-dioxobutyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




HO—


HO—





RN 138166-06-0 CAPLUS

CN β -Cyclodextrin, 6A-[[4-(benzoylamino)-1,4-dioxobutyl]amino]-6A-deoxy-
(9CI) (CA INDEX NAME)

L14 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1992:152238 CAPLUS
 DOCUMENT NUMBER: 116:152238
 TITLE: Vectorized transport of drugs: synthesis of a new
 glycosyl derivative of β - **cyclodextrin**
 AUTHOR(S): Parrot-Lopez, Helene; Galons, Herve; Coleman, Anthony
 W.; Mahuteau, Jacqueline; Miocque, Marcel
 CORPORATE SOURCE: Fac. Pharm., Univ. Rene Descartes, Paris, 75270, Fr.
 SOURCE: Tetrahedron Letters (1992), 33(2), 209-12
 CODEN: TELEAY; ISSN: 0040-4039
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 116:152238
 GI




AB Monosubstitution at the O-6 position of β - **cyclodextrin** by a
 β -N-glucosyl residue was achieved with a C9 diamide spacer as the
 interglycosidic linkage. The new glycosyl derivative I is much more soluble
 (200 g/L) in water but retains the capacity to include and to enhance the solubility
 of pharmacol. active mols.
 IT **139921-46-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation, solubility, and inclusion reaction of, with nicardipine)
 RN 139921-46-3 CAPLUS
 CN β -Cyclodextrin, 6A-deoxy-6A-[[9-(β -D-glucopyranosylamino)-1,9-
 dioxononyl]amino]- (9CI) (CA INDEX NAME)



L14 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1992:113525 CAPLUS
 DOCUMENT NUMBER: 116:113525
 TITLE: **Cyclodextrin** inclusion complexes as


INVENTOR(S): pharmaceutical carriers
 Weinshenker, Ned M.
 PATENT ASSIGNEE(S): Cyclex, Inc., USA
 SOURCE: U.S., 23 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	US 5068227	A	19911126	US 1989-298634	19890118
PRIORITY APPLN. INFO.:				US 1989-298634	19890118
AB	Cyclodextrins (I) are coupled to biorecognition mols. such as antibodies. The cyclodextrins so coupled provide a cavity or complexation zone into which active agents such as labels or drugs may be incorporated. The active agent forms a noncovalently bonded inclusion complex within the cavity of I and thus remains associated with I and the coupled biorecognition mol. and thus can be delivered to the other half of the biospecific recognition. IgG-polyglycine-6-(3-carboxypropanamido)-6-deoxy- β - cyclodextrin (II) (preparation is given) was added to methotrexate to obtain an I-II inclusion complex.				
IT	138141-88-5DP , conjugates with IgG 139143-66-1P 139143-67-2P 139143-68-3P 139143-69-4DP , conjugates with antibodies, complexes with chlorambucil 139143-70-7DP , conjugates with monoclonal antibody 139143-74-1DP , conjugates with IgG 139143-75-2DP , conjugates with IgG 139175-89-6P 139175-90-9DP , conjugates with monoclonal antibody 139175-91-0DP , reaction products with cyclodextrin derivs., conjugates with IgG RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN	138141-88-5 CAPLUS				
CN	β-Cyclodextrin , 6A-[(4-amino-1,4-dioxobutyl)amino]-6A-deoxy- (9CI) (CA INDEX NAME)				



RN 139143-66-1 CAPLUS
 CN α -Cyclodextrin, 6A-[[4-[[2-(4-aminophenyl)ethyl]amino]-1,4-dioxobutyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




—CH₂—OH


—OH

—OH

RN 139143-67-2 CAPLUS


CN β-Cyclodextrin, 6A-deoxy-6A-[[4-[[2-(4-isothiocyanatophenyl)ethyl]amino]-1,4-dioxobutyl]amino]- (9CI) (CA INDEX NAME)







HO—

HO—




RN 139143-68-3 CAPLUS
 CN γ -Cyclodextrin, 6A-deoxy-6A-[[4-[[2-(4-isothiocyanatophenyl)ethyl]amino]-1,4-dioxobutyl]amino]- (9CI) (CA INDEX NAME)






RN 139143-69-4 CAPLUS
 CN α -Cyclodextrin, 6A-[[4-[[2-[4-[(aminothioxomethyl)amino]phenyl]ethyl]amino]-1,4-dioxobutyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)




HO—

HO—




RN 139143-70-7 CAPLUS

CN β -Cyclodextrin, 6A-[[4-[[2-[4-[(aminothioxomethyl)amino]phenyl]ethyl]amino]-1,4-dioxobutyl]amino]-6A-deoxy- (9CI) (CA INDEX NAME)




PAGE 1-B




PAGE 2-A

HO—

HO—



RN 139143-74-1 CAPLUS


CN α -Cyclodextrin, 6A-[(4-amino-1,4-dioxobutyl)amino]-6A-deoxy- (9CI)
(CA INDEX NAME)

RN 139143-75-2 CAPLUS


CN γ -Cyclodextrin, 6A-[(4-amino-1,4-dioxobutyl)amino]-6A-deoxy- (9CI)
(CA INDEX NAME)

PAGE 1-A

HO—




PAGE 1-B



RN 139175-89-6 CAPLUS
 CN α -Cyclodextrin, 6A-deoxy-6A-[[4-[[2-(4-isothiocyanatophenyl)ethyl]amino]-1,4-dioxobutyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A



HO—

HO—


PAGE 1-B




RN 139175-90-9 CAPLUS

CN γ -Cyclodextrin, 6A-deoxy-6A-[[4-[[2-[4-[(aminothioxomethyl)amino]phenyl]ethyl]amino]-1,4-dioxobutyl]amino]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



RN 139175-91-0 CAPLUS
 CN γ -Cyclodextrin, 6A-deoxy-6A-[[4-(2,5-dioxo-1-pyrrolidinyl)-1,4-dioxobutyl]amino]- (9CI) (CA INDEX NAME)



PAGE 1-B



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9002141	A1	19900308	WO 1989-AU359	19890823
W: AU, BB, BG, BR, DK, FI, HU, JP, KP, KR, LK, MC, MG, MW, NO, RO, SD, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
AU 8944290	A1	19900323	AU 1989-44290	19890823
AU 693072	B2	19980625		
EP 431080	A1	19910612	EP 1989-911240	19890823
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
BR 8907625	A	19910820	BR 1989-7625	19890823
JP 04500229	T2	19920116	JP 1989-510576	19890823
CN 1040987	A	19900404	CN 1989-106650	19890830
DD 297833	A5	19920123	DD 1989-332260	19890831
ZA 8906624	A	19920129	ZA 1989-6624	19900830
US 5324750	A	19940628	US 1992-979451	19921120
PRIORITY APPLN. INFO.:			AU 1988-165	19880831
			AU 1988-189	19880901
			AU 1988-618	19880927
			AU 1988-1053	19881019
			AU 1988-1198	19881027
			AU 1988-1417	19881111
			AU 1989-4894	19890626
			AU 1989-4909	19890626
			AU 1989-5034	19890703
			AU 1989-5278	19890717
			AU 1989-5354	19890719
			AU 1989-5576	19890803
			AU 1989-5641	19890807
			AU 1989-5682	19890809
			WO 1989-AU359	19890823
			US 1991-684888	19910412
AB	Cyclodextrin derivs. are prepared, which form soluble and stable inclusion complexes and covalently-bonded compds. with drugs, pesticides and cosmetics. The cyclodextrin derivs. have ≥ 1 NH ₂ group substituted with OH at C-2, C-3, or C-6. 6A-O-p-Toluenesulfonyl- β - cyclodextrin prepared as usual, was treated with Na azide and 1,1,2,2-tetrachloroethane, to give 6A-azido-6A-deoxy- β - cyclodextrin , which was hydrogenated over Pd black, in water, to yield 6A-amino-6A-deoxy- β - cyclodextrin . This was treated with ibuprofen anhydride to give 6A-deoxy-6A-(α -methyl-4-isobutylphenylacetamido)- β - cyclodextrin , a prodrug for ibuprofen delivery. The cyclodextrin derivs. and their inclusion complexes may also be used for the chromatog. separation of enantiomers from racemic mixts.			
IT	130912-22-0P 130912-23-1P RL: THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, for drug delivery systems)			
RN	130912-22-0 CAPLUS			
CN	α -Cyclodextrin, 6A,6'A-[(1,4-dioxo-1,4-butanediyl)diimino]bis[6A-deoxy- (9CI) (CA INDEX NAME)			
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***				
RN	130912-23-1 CAPLUS			

CN β -Cyclodextrin, 6A,6'A-[(1,4-dioxo-1,4-butanediyl)diimino]bis[6A-deoxy- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L14 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1991:6998 CAPLUS

DOCUMENT NUMBER: 114:6998

TITLE: A new synthesis of **cyclodextrin** dimers

AUTHOR(S): Coates, John H.; Easton, Christopher J.; Van Eyk, Stephen J.; Lincoln, Stephen F.; May, Bruce L.; Whalland, Craig B.; Williams, Michael L.

CORPORATE SOURCE: Dep. Chem., Univ. Adelaide, Adelaide, 5001, Australia

SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1990), (9), 2619-20

CODEN: JCPRB4; ISSN: 0300-922X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 114:6998

AB The synthesis and characterization of $\text{NHCO}(\text{CH}_2)_n\text{CONH}$ ($n = 2, 3$ for β , $n = 2$ for α) linked **cyclodextrins** is reported.

IT 130912-22-0P 130912-23-1P 130912-24-2P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as potential inclusion complex)

RN 130912-22-0 CAPLUS

CN α -Cyclodextrin, 6A,6'A-[(1,4-dioxo-1,4-butanediyl)diimino]bis[6A-deoxy- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 130912-23-1 CAPLUS

CN β -Cyclodextrin, 6A,6'A-[(1,4-dioxo-1,4-butanediyl)diimino]bis[6A-deoxy- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 130912-24-2 CAPLUS

CN β -Cyclodextrin, 6A,6'A-[(1,5-dioxo-1,5-pentanediy)diimino]bis[6A-deoxy- (9CI) (CA INDEX NAME)

